Family offices ramp up deals in June with bets on biotech and pharma

0
5


Key Points

  • After a slow spring, investment firms of the ultra-rich made 60 direct investments in June, according to Fintrx.
  • Family offices flocked to biotech and health-care firms such as Antheia, seeking to make an impact and returns at the same time.
  • Antheia founder Christina Smolke told CNBC’s Inside Wealth family offices’ patient capital makes them a good fit for investing in scientific breakthroughs.


LEAVE A REPLY

Please enter your comment!
Please enter your name here